In a landmark advancement for oncology, researchers from University College London (UCL) and University College London Hospitals (UCLH) have reported extraordinary long-term success in treating a specific subset of bowel cancer using a short course of pre-surgical immunotherapy. Findings from the NEOPRISM-CRC clinical trial reveal that patients who received the immunotherapy drug pembrolizumab prior to surgery remained free of cancer recurrence for nearly three years, significantly outperforming the benchmarks set by traditional treatment regimens.
The results, which are slated for formal presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, suggest a paradigm shift in how clinicians approach stage two and three bowel cancers, potentially sparing patients from the gruelling side effects of traditional post-operative chemotherapy.
The NEOPRISM-CRC Trial: A New Frontier in Oncology
Bowel cancer remains the fourth most common malignancy in the United Kingdom, accounting for approximately 44,000 new diagnoses annually. While survival rates have improved with early detection—boasting a 90% five-year survival rate for stage one disease—the prognosis for later stages remains challenging. For stage three, survival rates drop to 65%, and for stage four, they plummet to 10%.
The NEOPRISM-CRC trial focused on a specific genetic profile: MMR-deficient (mismatch repair deficient) or MSI-high (microsatellite instability-high) bowel cancer. This genetic signature, which affects roughly 10-15% of patients with stage two or three disease, is often more aggressive and prone to recurrence. By targeting this specific molecular vulnerability, the trial sought to replace the standard "surgery-first" model, which is typically followed by months of adjuvant chemotherapy, with a more targeted, biological approach.
Chronology of a Medical Breakthrough
The trajectory of the NEOPRISM-CRC trial began with the recruitment of 32 patients across five major UK medical centers, including University Hospital Southampton, St. James’s University Hospital in Leeds, and the Christie NHS Foundation Trust in Manchester.
Phase I: The Pre-Surgical Intervention
Participants were administered pembrolizumab—an immunotherapy agent designed to "unmask" cancer cells so the immune system can identify and destroy them—for a duration of up to nine weeks prior to their scheduled bowel surgery. This "neoadjuvant" approach was intended to shrink the tumor and eradicate micro-metastases before the primary surgical intervention occurred.
Phase II: Surgical Intervention and Monitoring
Following the nine-week immunotherapy course, patients underwent standard bowel surgery. Initial reports were highly promising, with 59% of patients showing no detectable signs of disease post-surgery.
Phase III: The 33-Month Milestone
The most recent data, covering a follow-up period of 33 months, has surpassed initial expectations. Remarkably, 100% of the trial participants remained cancer-free. This success was consistent regardless of whether patients had shown a complete response immediately post-surgery or if small traces of disease were initially suspected. In cases where minimal disease remained, the cancer failed to grow or spread, suggesting the immunotherapy had effectively "quiesced" the malignancy.
Comparative Efficacy: Challenging the Standard of Care
To understand the magnitude of this achievement, it is necessary to compare it against the current gold standard. Under traditional protocols, patients undergo surgery followed by three to six months of chemotherapy. Despite this aggressive approach, clinical data indicates that approximately 25% of patients experience a relapse within three years.
By replacing this cycle with a brief, nine-week course of immunotherapy, the NEOPRISM-CRC researchers have demonstrated that it is possible to achieve more durable cancer control. The absence of recurrence in the trial cohort suggests that the immune system, once primed by pembrolizumab, may provide a lasting "surveillance" mechanism that standard chemotherapy simply cannot replicate.
Personalized Blood Tests: The Key to Precision Medicine
A significant portion of the recent research, supported by biotechnology company Personalis, focused on translational biology—the study of why and how this treatment works. The research team developed personalized blood tests capable of detecting circulating tumor DNA (ctDNA).
The team discovered a direct correlation between the clearance of tumor DNA from the bloodstream and the long-term clinical outcome. When tumor DNA disappeared from the blood, patients were significantly more likely to have achieved a complete pathological response. Furthermore, researchers performed immune profiling on tumor tissue prior to the first cycle of treatment, finding that the baseline state of a patient’s immune environment could serve as a predictive biomarker.
These tools represent a critical step toward "precision oncology," allowing clinicians to determine in real-time whether a patient is responding to treatment or if they require a more aggressive, tailored escalation of care.
Official Perspectives: Translating Science into Practice
The leadership behind the NEOPRISM-CRC trial emphasizes that these findings are not merely academic—they are life-changing.
Dr. Kai-Keen Shiu, Chief Investigator of the trial and a Consultant Medical Oncologist at UCLH, highlighted the emotional and clinical weight of the data. "Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging," he stated. "It strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers."
Dr. Shiu emphasized the practical application of the research: "What is particularly exciting is that we now may be able to predict who will respond to the treatment using personalized blood tests and immune profiling. These tools could help us tailor our approach, identifying patients who are doing well and may need less therapy… versus patients at higher risk of disease progression."
Professor Marnix Jansen, who led the translational research, noted the duality of the findings. "These results not only confirm the durability of responses we saw almost three years ago, but also provide crucial biological insights into why immunotherapy is so effective in this setting."
Yanrong Jiang, the lead author of the research abstract, echoed this sentiment: "We were thrilled to be able to follow patients very closely using the personalized blood tests. When tumor DNA disappeared from the blood, patients were much more likely to have no cancer remaining. We hope these tests may be used to guide treatment decisions in a more practical and timely way."
Patient Impact: A Case Study in Success
The human impact of the trial is best illustrated by the experience of Christopher Burston, a 73-year-old from Dorset. Diagnosed in early 2023 following a positive result from a routine home-screening kit, Burston was identified as having stage three bowel cancer.
"I saw the images when I had the first colonoscopy and could see it was really quite a substantial lump," Burston recalled. "It wasn’t a minor thing."
After enrolling in the NEOPRISM-CRC trial, Burston received three doses of pembrolizumab over nine weeks. When he underwent surgery in May 2023, the results were astounding. "The outcome of the surgery was essentially that the cancer had melted away," he said, citing the surgeon’s own words.
Now, more than three years post-diagnosis, Burston is living a full, active life. "I feel very lucky that I’ve reached the stage where my main problem is age rather than cancer or any illness," he remarked, underscoring the profound difference between surviving with the toxic side effects of traditional chemotherapy and the high-quality recovery enabled by the trial’s protocol.
Future Implications for Global Health
The success of the NEOPRISM-CRC trial serves as a clarion call for a larger, multi-center phase III trial. If the results are replicated in a larger population, it could lead to a fundamental change in clinical guidelines.
The implications are threefold:
- Quality of Life: Patients avoid the physical and psychological toll of prolonged post-operative chemotherapy.
- Economic Efficiency: A nine-week immunotherapy course, while expensive, may prove more cost-effective than the prolonged hospital stays and complications associated with traditional multi-modal treatment.
- Biological Insight: The validation of ctDNA as a reliable marker for cancer clearance allows for a "watch and wait" strategy, where unnecessary surgeries or additional treatments can be avoided.
As the medical community prepares for the AACR Annual Meeting in April 2026, the NEOPRISM-CRC trial stands as a testament to the power of molecular profiling. By matching the right patient to the right immunotherapy at the right time, researchers are moving closer to a future where bowel cancer is not just treatable, but consistently curable.
